98%
921
2 minutes
20
Background: Screening of malignant hematological diseases is of great importance for their diagnosis and subsequent treatment. This study constructed an optimal screening model for malignant hematological diseases based on routine blood cell parameters.
Methods: The venous blood samples of 1751 patients collected from 10 tertiary hospitals in China were divided into a training set (1223 cases) and a validation set (528 cases). In addition to the clinical diagnostic information of the samples in the training set, 26 blood cell parameters including morphological parameters were selected using manual screening and filtering to construct eight machine learning models. These models were used to identify hematological malignancies among the validation set.
Results: Comparison of the discrimination, calibration and clinical detection performance of the eight machine learning models revealed that the artificial neural network (ANN) model performed the optimal in identifying malignant haematological diseases in the validation set (528 cases), with an area under the receiver operating characteristic curve (AUC), accuracy, sensitivity and specificity of 0.906, 0.857, 0.832 and 0.884, respectively.
Conclusion: The ANN model constructed can be used for screening of malignant hematological diseases, especially in primary hospitals that lack comprehensive diagnosis, and this ANN model will help patients to get diagnosis and treatment of malignant hematological diseases as early as possible.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816569 | PMC |
http://dx.doi.org/10.1186/s12911-025-02892-1 | DOI Listing |
J Med Chem
September 2025
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92093, United States.
Proteasome inhibitors are effective in treating hematologic cancers but have limited utility in brain tumors due to poor blood-brain barrier (BBB) penetration and metabolic instability. In this study, we developed novel macrocyclic peptide epoxyketone inhibitors with improved drug-like properties. Compounds were screened for cytotoxicity against brain cancer cell lines, permeability (PAMPA-BBB and Caco-2), and metabolic stability.
View Article and Find Full Text PDFBMC Res Notes
September 2025
Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Objectives: Small cell lung cancer (SCLC) accounts for approximately 15% of lung tumors and is marked by aggressive growth and early metastatic spread. In this study, we used two SCLC mouse models with differing tumor mutation burdens (TMB). To investigate tumor composition, spatial architecture, and interactions with the surrounding microenvironment, we acquired multiplexed images of mouse lung tumors using imaging mass cytometry (IMC).
View Article and Find Full Text PDFBreast Cancer Res
September 2025
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Background: Polygenic risk scores (PRS) are not yet standard in clinical risk assessments for familial breast cancer in Sweden. This study evaluated the distribution and impact of an established PRS (PRS) in women undergoing clinical sequencing for hereditary breast cancer.
Findings: We integrated PRS into a hereditary breast cancer gene panel used in clinical practice and calculated scores for 262 women.
J Int Med Res
September 2025
Department of Hematology, Guangzhou Eighth People's Hospital, Guangzhou Medical University, China.
ObjectiveAccurate prognostication is crucial for managing human immunodeficiency virus (HIV)-associated cutaneous T-cell lymphoma. In this study, we aimed to develop an improved machine learning-based prognostic model for predicting the 5-year survival rates in HIV-associated cutaneous T-cell lymphoma patients.MethodsWe derived and tested machine learning models using algorithms including Extreme Gradient Boosting (XGBoost), Light Gradient Boosting Machine (LightGBM), and Random Forest.
View Article and Find Full Text PDFZhonghua Bing Li Xue Za Zhi
September 2025
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
To investigate the clinicopathological features, diagnosis, and prognosis of aggressive natural killer-cell leukemia (ANKL). A retrospective analysis was conducted on 27 ANKL patients treated at the First Affiliated Hospital of Nanjing Medical University from 2014 to 2024. Their clinical data, histomorphology, and immunophenotype were reviewed.
View Article and Find Full Text PDF